SYRE - Spyre Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$85.45
DETAILS
HIGH:
$107.00
LOW:
$49.00
MEDIAN:
$90.00
CONSENSUS:
$85.45
UPSIDE:
15.40%
Profitability Ratios
| Ratio | Value |
|---|---|
| GP Margin | 0.0% |
| EBIT Margin | 0.0% |
| EBITDA Margin | 0.0% |
| Operating Margin | 0.0% |
| Pretax Margin | 0.0% |
| Cont. Ops Margin | 0.0% |
| Net Margin | 0.0% |
| Bottom Line Margin | 0.0% |
Liquidity Ratios
| Ratio | Value |
|---|---|
| Current Ratio | 13.25 |
| Quick Ratio | 13.25 |
| Solvency Ratio | -2.322 |
| Cash Ratio | 1.46 |
Valuation Ratios
| Ratio | Value |
|---|---|
| Price/Earnings |
-73.04
Peers avg: 33.0
|
| PEG Ratio | 1.94 |
| Forward PEG | 1.94 |
| Price/Book | 15.85 |
| Price/Sales | 0.00 |
| Price/FCF | -66.98 |
| Price/Op Cash Flow | -66.98 |
Debt Ratios
| Ratio | Value |
|---|---|
| Debt/Assets | 0.0000 |
| Debt/Equity | 0.0000 |
| Debt/Capital | 0.0000 |
| Long-Term Debt/Capital | 0.0000 |
| Financial Leverage | 1.09 |
Cash Flow Ratios
| Ratio | Value |
|---|---|
| Working Capital Turnover | 0.00 |
| Operating Cash Flow Ratio | -2.884 |
| Operating Cash Flow/Sales | 0.0% |
| Free Cash Flow/Operating Cash Flow | 100.0% |
Coverage Ratios
| Ratio | Value |
|---|---|
| Debt Service Coverage | 0.00 |
| Interest Coverage | 0.0000 |
| Short-Term Operating Cash Flow Coverage | 0.00 |
| Operating Cash Flow Coverage | 0.00 |
| Capital Expenditure Coverage | 0.00 |
| Dividend + Capital Expenditure Coverage | 0.00 |
Dividend Ratios
| Ratio | Value |
|---|---|
| Payout Ratio | 0.0000% |
| Dividend Yield | 0.0000% |
| Dividend Yield % | 0.0000% |
| Dividend Per Share | 0.0000 |
Per Share Ratios
| Ratio | Value |
|---|---|
| Revenue/Share | 0.00 |
| EPS | -0.449 |
| Debt/Share | 0.0000 |
| Cash/Share | 2.19 |
| Book Value/Share | 2.07 |
| Tangible BV/Share | 2.07 |
| Equity/Share | 2.07 |
| Operating Cash Flow/Share | -0.489 |
| Capital Expenditure/Share | 0.000 |
| FCF/Share | -0.489 |
Other Ratios
| Ratio | Value |
|---|---|
| Net Income/Earnings Before Tax | 1.000 |
| Earnings Before Tax/EBIT | 0.741 |
| Price/Fair Value | 15.85 |
| Debt/Market Cap | 0.0000 |
| Effective Tax Rate | 0.0% |
| Enterprise Value Multiple | -53.69 |